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OBJECTIVES: This study was designed to enhance our
understanding of the burden of diabetes in the US. 
METHODS: We analyzed age-speciﬁc odds ratios, 
relative mortality rates ratios (RMRR), changes in
RMRR, prevalence, case-fatality and health care utiliza-
tion associated with combinations of 1, 2, 3, 4, and 5
concomitant diseases in diabetes, such as cardiovascular,
cerebrovascular, cancers, infectious, respiratory and
central nervous system disorders. Combinations of 
multivariate linear and logistic regression models, stan-
dard SAS procedures and original linear true basic models
were applied to a data bank system containing data in
relational and SAS formats drawn from the 1991–1996
Multiple Causes of Death Files, 1996 Medical Expendi-
ture Panel Survey, and 1987 National Medical Expendi-
ture Survey. 
RESULTS: From 1991 to 1996, the proportion of deaths
among diabetes patients <65 years grew 8.3%. The 
age group “25–29” was characterized by an estimated
61% increase in the relative mortality rate ratio of 1.5.
Respiratory conditions were associated with an estimated
23.5% of deaths among diabetes patients, compared to
23% for cerebrovascular disease. Primary causes of death
in diabetes patients increased for ischemic heart disease
(estimated 69% growth), atherosclerosis (43%), all 
respiratory conditions, including COPD (33%), breast
cancer (33%), septicemia (26%) and acute cerebrovascu-
lar disease (11%). This resulted in premature diabetic
mortality cost estimated at $3.2 billion in 1996. The 
estimated annual direct cost of treating high-risk diabetes
patients reached $36 billion, 54% of which was paid by
Medicare and Other Federal Programs. 
CONCLUSIONS: Based on the estimated increases in
case-fatality and mortality rates within employable age
groups, treatment of diabetes with concomitant cardio-
vascular, respiratory, breast cancer, cerebrovascular and
infectious diseases did not improve in the early 1990s.
Much opportunity remains for improving mortality in
diabetes. 
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Published utility estimates can vary over a wide range
even for the same level of disease severity. As a result,
cost-utility analysts seeking secondary utilities have 
difﬁculty choosing appropriate weights for QALYs. 
OBJECTIVES: We performed two meta-analyses to
derive pooled utilities for AIDS, symptomatic HIV, and
asymptomatic HIV and minor, moderate, and major
stroke. In addition, we sought to assess the relative 
importance of study design characteristics in predicting
utility. 
METHODS: We identiﬁed 26 articles reporting 75
unique utilities for HIV/AIDS and 20 articles reporting
53 utilities for stroke. Multiple utility estimates often
appeared in the same article so that data were nested.
Consequently, we used a Hierarchical Linear Model to
perform each meta-analysis. Lacking the variance, studies
were weighted by sample size. 
RESULTS: For HIV/AIDS, disease stage (P = 0.016) and
respondents (P = 0.014) were signiﬁcant predictors of
utility while elicitation method (P < 0.1) was marginally
signiﬁcant and scale bounds were not. Pooled utility 
estimates are 0.71 for AIDS, 0.82 for symptomatic HIV,
and 0.93 for asymptomatic HIV when the time tradeoff
method is used in patients and the scale is death to perfect
health. For stroke, severity of stroke (P < 0.0001) and
scale bounds (P = 0.0015) were signiﬁcant predictors of
utility, while the elicitation method and respondents were
not. Pooled utility estimates are 0.52 for major stroke,
0.68 for moderate stroke, and 0.87 for minor stroke when
the time tradeoff method is used in community members
and the scale is death to perfect health. 
CONCLUSION: Because the pooled utility estimates
reported here are based on a comprehensive review of 
the literature, they should be of great use to researchers
performing cost-utility analyses of interventions for
HIV/AIDS as well as those designed to prevent or treat
stroke, or where stroke is a possible side effect of therapy.
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At the 2001 ISPOR Annual Meeting we presented a 
stochastic decision analysis of treatment of pyelone-
phritis with ciproﬂoxacin or trimethoprim sulphame-
thoxazole (TMP/SMX) based on an RCT. 
OBJECTIVE: Using the same dataset, the purpose of this
study is to analyze the value of funding research to reduce
the uncertainty around the decision about which drug to
prescribe. 
